• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

纳布西莫尔对多发性硬化症患者步行能力的改善作用。

Walking improvements with nabiximols in patients with multiple sclerosis.

作者信息

Coghe G, Pau M, Corona F, Frau J, Lorefice L, Fenu G, Spinicci G, Mamusa E, Musu L, Massole S, Massa R, Marrosu M G, Cocco E

机构信息

Department of Public Health, Clinical and Molecular Medicine, University of Cagliari, Cagliari, Italy.

Department of Mechanical, Chemical and Materials Engineering, University of Cagliari, Cagliari, Italy.

出版信息

J Neurol. 2015 Nov;262(11):2472-7. doi: 10.1007/s00415-015-7866-5. Epub 2015 Aug 5.

DOI:10.1007/s00415-015-7866-5
PMID:26239223
Abstract

Recently, nabiximols was approved as a treatment in MS spasticity. Data leading to approval and clinical use of nabiximols, although widely recognised, are based on subjective scales. Movement analysis procedures would obtain more detailed data about the impact on mobility. The aim of the study was to quantitatively assess the functional modification of gait patterns induced by nabiximols in MS. We evaluated three-dimensional gait analysis (spatial-temporal and kinematic) variation by means of one-way ANOVA. Twenty patients were enrolled-9 male and 11 female-with mean EDSS of 5.3 (SD ± 0.81) and mean reduction of numerical rating scale during nabiximols treatment of 1.88. The spatial-temporal parameters of gait revealed an increased speed (+15 %, p < 0.001), cadence (+6 %, p < 0.001) and stride length (+10 %, p < 0.001) after treatment. Regarding the kinematics data, the Gait Profile Score after treatment was reduced by 10 % (p < 0.001): Significant changes involved the pelvic area, hip rotation and knee flexion-extension. We found that nabiximols is able to improve the speed, cadence and stride length. Furthermore, the dynamics of the proximal segment of the legs and the knee movement results after treatment are closer to the physiologic values.

摘要

最近,纳比西莫尔被批准用于治疗多发性硬化症痉挛。导致纳比西莫尔获批及临床应用的数据虽广为人知,但基于主观量表。运动分析程序将获取有关其对活动能力影响的更详细数据。本研究的目的是定量评估纳比西莫尔对多发性硬化症患者步态模式的功能改变。我们通过单因素方差分析评估三维步态分析(时空和运动学)变化。纳入了20名患者,其中9名男性和11名女性,平均扩展残疾状态量表(EDSS)评分为5.3(标准差±0.81),在纳比西莫尔治疗期间数字评定量表平均降低了1.88。步态的时空参数显示,治疗后速度增加了15%(p<0.001)、步频增加了6%(p<0.001)、步长增加了10%(p<0.001)。关于运动学数据,治疗后的步态轮廓评分降低了10%(p<0.001):显著变化涉及骨盆区域、髋关节旋转和膝关节屈伸。我们发现纳比西莫尔能够提高速度、步频和步长。此外,治疗后腿部近端节段的动力学和膝关节运动结果更接近生理值。

相似文献

1
Walking improvements with nabiximols in patients with multiple sclerosis.纳布西莫尔对多发性硬化症患者步行能力的改善作用。
J Neurol. 2015 Nov;262(11):2472-7. doi: 10.1007/s00415-015-7866-5. Epub 2015 Aug 5.
2
A randomized, double-blind, placebo-controlled trial to evaluate the effect of nabiximols oromucosal spray on clinical measures of spasticity in patients with multiple sclerosis.一项随机、双盲、安慰剂对照试验,旨在评估纳比昔单抗口腔喷雾剂对多发性硬化症患者痉挛临床指标的影响。
Mult Scler Relat Disord. 2024 Sep;89:105740. doi: 10.1016/j.msard.2024.105740. Epub 2024 Jun 20.
3
Tetrahydrocannabinol and cannabidiol oromucosal spray in resistant multiple sclerosis spasticity: consistency of response across subgroups from the SAVANT randomized clinical trial.大麻二酚和四氢大麻酚口腔黏膜喷雾剂治疗多发性硬化痉挛:SAVANT 随机临床试验亚组间的一致性反应。
Int J Neurosci. 2020 Dec;130(12):1199-1205. doi: 10.1080/00207454.2020.1730832. Epub 2020 Mar 1.
4
Short and long term effects of Nabiximols on balance and walking assessed by 3D-gait analysis in people with Multiple Sclerosis and spasticity.通过三维步态分析评估纳布西莫尔对多发性硬化症和痉挛患者平衡及行走能力的短期和长期影响。
Mult Scler Relat Disord. 2021 Jun;51:102805. doi: 10.1016/j.msard.2021.102805. Epub 2021 Jan 30.
5
Effect of spasticity on kinematics of gait and muscular activation in people with Multiple Sclerosis.痉挛对多发性硬化症患者步态运动学及肌肉激活的影响。
J Neurol Sci. 2015 Nov 15;358(1-2):339-44. doi: 10.1016/j.jns.2015.09.352. Epub 2015 Sep 18.
6
Effect of nabiximols on Goal Attainment Scale scores in patients with treatment-resistant multiple sclerosis spasticity.纳比昔单抗对治疗抵抗性多发性硬化痉挛患者目标达成量表评分的影响。
Neurodegener Dis Manag. 2021 Apr;11(2):143-153. doi: 10.2217/nmt-2020-0060. Epub 2021 Mar 1.
7
Predictors of Nabiximols (Sativex) discontinuation over long-term follow-up: a real-life study.长期随访中停用 Nabiximols(Sativex)的预测因素:一项真实世界研究。
J Neurol. 2020 Jun;267(6):1737-1743. doi: 10.1007/s00415-020-09739-x. Epub 2020 Mar 2.
8
Long-term assessment of the cognitive effects of nabiximols in patients with multiple sclerosis: A pilot study.长期评估纳比昔单抗对多发性硬化症患者认知影响的前瞻性研究:一项初步研究。
Clin Neurol Neurosurg. 2020 Sep;196:105990. doi: 10.1016/j.clineuro.2020.105990. Epub 2020 Jun 5.
9
The role of Sativex in robotic rehabilitation in individuals with multiple sclerosis: Rationale, study design, and methodology.Sativex在多发性硬化症患者机器人康复中的作用:理论依据、研究设计与方法
Medicine (Baltimore). 2017 Nov;96(46):e8826. doi: 10.1097/MD.0000000000008826.
10
Quantitative assessment of the effects of 6 months of adapted physical activity on gait in people with multiple sclerosis: a randomized controlled trial.对多发性硬化症患者进行6个月适应性体育活动对步态影响的定量评估:一项随机对照试验。
Disabil Rehabil. 2018 Jan;40(2):144-151. doi: 10.1080/09638288.2016.1244291. Epub 2017 Jan 13.

引用本文的文献

1
Cannabinoids for spasticity in patients with multiple sclerosis: A systematic review and meta-analysis.大麻素用于治疗多发性硬化症患者的痉挛:一项系统评价和荟萃分析。
Mult Scler J Exp Transl Clin. 2024 Nov 5;10(4):20552173241282379. doi: 10.1177/20552173241282379. eCollection 2024 Oct-Dec.
2
Effect of nabiximols oromucosal spray (Sativex) on symptoms associated with multiple sclerosis-related spasticity: a case series.纳布西莫尔口腔喷雾剂(Sativex)对与多发性硬化相关痉挛有关症状的影响:病例系列研究
Drugs Context. 2024 Feb 14;13. doi: 10.7573/dic.2023-10-1. eCollection 2024.
3
Patient-reported benefits from nabiximols treatment in multiple sclerosis-related spasticity exceed conventional measures.

本文引用的文献

1
Gait Deviation Index, Gait Profile Score and Gait Variable Score in children with spastic cerebral palsy: Intra-rater reliability and agreement across two repeated sessions.痉挛型脑瘫患儿的步态偏差指数、步态轮廓评分和步态变量评分:两次重复测量的评分者内信度及一致性
Gait Posture. 2015 Jul;42(2):133-7. doi: 10.1016/j.gaitpost.2015.04.019. Epub 2015 May 11.
2
Use of gait parameters to predict the effectiveness of botulinum toxin injection in the spastic rectus femoris muscle of stroke patients with stiff knee gait.利用步态参数预测肉毒杆菌毒素注射对膝部僵硬步态的中风患者痉挛性股直肌的疗效。
Eur J Phys Rehabil Med. 2015 Aug;51(4):361-70. Epub 2014 Sep 12.
3
患者报告纳比西莫司治疗多发性硬化相关痉挛的益处超过传统措施。
Neurodegener Dis Manag. 2024 Feb;14(1):11-20. doi: 10.2217/nmt-2023-0040. Epub 2024 Feb 6.
4
The Therapeutic Potential and Molecular Mechanisms Underlying the Neuroprotective Effects of Sativex - A Cannabis-derived Spray.欣百达(盐酸度洛西汀肠溶胶囊)治疗纤维肌痛的有效性和安全性:一项为期 12 周、随机、双盲、安慰剂对照研究
Mini Rev Med Chem. 2024;24(15):1427-1448. doi: 10.2174/0113895575285934240123110158.
5
Cannabinoids in Medicine: A Multifaceted Exploration of Types, Therapeutic Applications, and Emerging Opportunities in Neurodegenerative Diseases and Cancer Therapy.医学中的大麻素:对类型、治疗应用以及神经退行性疾病和癌症治疗中新兴机遇的多方面探索。
Biomolecules. 2023 Sep 14;13(9):1388. doi: 10.3390/biom13091388.
6
Change in upper limb function in people with multiple sclerosis treated with nabiximols: a quantitative kinematic pilot study.多发性硬化症患者接受纳比昔单抗治疗后上肢功能的变化:一项定量运动学的初步研究。
Neurol Sci. 2023 Feb;44(2):685-691. doi: 10.1007/s10072-022-06456-3. Epub 2022 Oct 19.
7
Dietary Supplementation With Oil Promotes Remyelination in a Mouse Model of Multiple Sclerosis.在多发性硬化症小鼠模型中,用油进行膳食补充可促进髓鞘再生。
Front Neurosci. 2022 May 2;16:860280. doi: 10.3389/fnins.2022.860280. eCollection 2022.
8
Immune Responses Regulated by Cannabidiol.大麻二酚调节的免疫反应。
Cannabis Cannabinoid Res. 2020 Feb 27;5(1):12-31. doi: 10.1089/can.2018.0073. eCollection 2020 Mar 1.
9
[What is new in symptomatic MS treatment: Part 2-gait disorder and spasticity].症状性多发性硬化症治疗的新进展:第2部分——步态障碍与痉挛
Nervenarzt. 2017 Dec;88(12):1428-1434. doi: 10.1007/s00115-017-0439-3.
10
Delta-9-Tetrahydrocannabinol/Cannabidiol Oromucosal Spray (Sativex): A Review in Multiple Sclerosis-Related Spasticity.Δ9-四氢大麻酚/大麻二酚口腔喷雾剂(Sativex):用于多发性硬化相关痉挛的综述。
Drugs. 2017 Apr;77(5):563-574. doi: 10.1007/s40265-017-0720-6.
Novel characterization of gait impairments in people with multiple sclerosis by means of the gait profile score.
通过步态轮廓评分对多发性硬化症患者步态障碍的新特征描述。
J Neurol Sci. 2014 Oct 15;345(1-2):159-63. doi: 10.1016/j.jns.2014.07.032. Epub 2014 Jul 19.
4
Nabiximols (THC/CBD oromucosal spray, Sativex®) in clinical practice--results of a multicenter, non-interventional study (MOVE 2) in patients with multiple sclerosis spasticity.纳布西莫尔(四氢大麻酚/大麻二酚口腔黏膜喷雾剂,商品名:萨替维克斯)在临床实践中的应用——一项针对多发性硬化症痉挛患者的多中心、非干预性研究(MOVE 2)的结果
Eur Neurol. 2014;71(5-6):271-9. doi: 10.1159/000357427. Epub 2014 Feb 12.
5
THC:CBD spray and MS spasticity symptoms: data from latest studies.THC:CBD 喷雾和多发性硬化痉挛症状:最新研究数据。
Eur Neurol. 2014;71 Suppl 1:4-9. doi: 10.1159/000357742. Epub 2014 Jan 22.
6
Clinical experience with THC:CBD oromucosal spray in patients with multiple sclerosis-related spasticity.四氢大麻酚:大麻二酚口腔黏膜喷雾剂治疗多发性硬化相关痉挛患者的临床经验
Int J Neurosci. 2014 Sep;124(9):652-6. doi: 10.3109/00207454.2013.877460. Epub 2014 Jan 23.
7
Test-retest reliability of three dimensional gait analysis: including a novel approach to visualising agreement of gait cycle waveforms with Bland and Altman plots.三维步态分析的重测信度:包括一种新的方法,用于使用 Bland 和 Altman 图可视化步态周期波形的一致性。
Gait Posture. 2014 Jan;39(1):265-71. doi: 10.1016/j.gaitpost.2013.07.130. Epub 2013 Sep 17.
8
Risk factors for falls in multiple sclerosis: an observational study.多发性硬化症患者跌倒的风险因素:一项观察性研究。
Mult Scler. 2013 Dec;19(14):1913-22. doi: 10.1177/1352458513488233. Epub 2013 Apr 30.
9
A new multiple sclerosis spasticity treatment option: effect in everyday clinical practice and cost-effectiveness in Germany.一种新的多发性硬化症痉挛治疗选择:在日常临床实践中的效果和德国的成本效益。
Expert Rev Neurother. 2013 Feb;13(3 Suppl 1):15-9. doi: 10.1586/ern.13.1.
10
Spasticity in multiple sclerosis: results of a patient survey.多发性硬化症中的痉挛:一项患者调查结果
Int J Neurosci. 2013 Jun;123(6):400-8. doi: 10.3109/00207454.2012.762364. Epub 2013 Feb 18.